Capital Impact Advisors’s Pacific Biosciences PACB Stock Holding History

Capital Impact Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-112,567	Closed	-$422K	–	86
2024 Q1	$422K	Sell	112,567 -33,007	-23%	-$193K	0.55%	75
2023 Q4	$1.43M	Buy	145,574 +121,999	+517%	+$998K	1.88%	7
2023 Q3	$197K	Hold	23,575	–	–	0.33%	100
2023 Q2	$314K	Hold	23,575	–	–	0.34%	133
2023 Q1	$273K	Buy	23,575 +10,408	+79%	+$103K	0.33%	135
2022 Q4	$108K	Hold	13,167	–	–	0.11%	218
2022 Q3	$140K	Buy	+13,167	New	+$75.5K	0.14%	209
2021 Q1	–	Sell	-300,000	Closed	-$7.78M	–	126
2020 Q4	$7.78M	Buy	+300,000	New	+$5.1M	1.91%	10
2015 Q1	–	Sell	-26,437	Closed	-$207K	–	291
2014 Q4	$207K	Hold	26,437	–	–	0.1%	111
2014 Q3	$130	Hold	26,437	–	–	﹤0.01%	183
2014 Q2	$163K	Buy	+26,437	New	+$132K	0.12%	156

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Impact Advisors's PACB Position: Q2 2024 in Review

Capital Impact Advisors sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 112,567 shares — an estimated $422K sold.

Capital Impact Advisors first reported a position in PACB in Q2 2014 and held it in 11 quarters. The position peaked at $7.78M in Q4 2020. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

Capital Impact Advisors reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
Capital Impact Advisors sold 112,567 Pacific Biosciences shares in Q2 2024, an estimated $422K.
Capital Impact Advisors first reported a position in Pacific Biosciences in Q2 2014 and held it in 11 quarters.
Capital Impact Advisors's Pacific Biosciences position peaked at $7.78M in Q4 2020.
228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Capital Impact Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.